Table 2 MenACWY-specific rSBA, IgG, and IgM responses following booster MenACWY-TT vaccination

From: Immunogenicity of primary and booster MenACWY-TT vaccination in older adults and the importance of IgM

Booster cohort; n = 104

Timepoint

  

Serogroup

Pre-

1 m

1 y (i.e., pre-booster)

1 y + 1 m

1 y + 1 y

MenA

rSBA GMT [95% CI]

4.7 [3.4–6.4]

1635.2 [1153.4–2318.1]

115.3 [70.3––189.0]

793.1 [575.9–1092.3]

291.9 [189.5–449.5]

 

rSBA ≥8% [95% CI]

21.2 [14.4–30.0]

98.1 [93.3–99.5]

77.9 [69.0–84.8]

98.1 [93.3–99.5]****

91.3 [84.2–95.3]

 

rSBA ≥128% [95% CI]

9.6 [5.3–16.8]

92.3 [85.6–96.1]

60.6 [51.0–69.4]

88.5 [80.9–93.3]****

74.8 [65.6–82.2]

 

IgG GMC [95% CI]; (µg/ml)

0.51 [0.39–0.67]

35.51 [24.63–51.21]

7.67 [5.28–11.13]

50.84 [38.53–67.09]

16.74 [12.23–22.92]

 

IgM GMC [95% CI]; (µg/ml)

0.17 [0.13–0.21]

3.79 [2.83–5.07]

0.91 [0.70–1.17]

2.72 [2.12–3.48]

1.72 [1.41–2.10]

MenC

rSBA GMT [95% CI]

3.6 [2.7–4.9]

1676.9 [1070.7–2626.5]

119.7 [74.4–192.7]

426.3 [287.6–631]

71.5 [43.4–118.0]

 

rSBA ≥8% [95% CI]

15.4 [9.7–23.5]

98.1 [93.3–99.5]

82.7 [74.3–88.8]

95.2 [89.2–97.9]

74.8 [65.6–82.2]###

 

rSBA ≥128% [95% CI]

7.7 [3.9–14.4]

84.6 [76.5–90.3]

54.8 [45.2–64.0]

80.8 [72.2–87.2]***

46.6 [37.3–56.2]####

 

IgG GMC [95% CI]; (µg/ml)

0.17 [0.13–0.22]

7.06 [5.13–9.70]

1.62 [1.20–2.18]

8.76 [7.14–10.75]

1.31 [0.99–1.73]

 

IgM GMC [95% CI]; (µg/ml)

0.06 [0.05–0.08]

1.56 [1.14–2.13]

0.27 [0.22–0.34]

0.49 [0.40–0.60]

0.22 [0.18–0.27]

MenW

rSBA GMT [95% CI]

3.2 [2.5–4.1]

923.5 [622.0–1371.2]

141.0 [87.2–227.8]

1373.0 [1007.1–1871.7]

242.6 [159.6–368.8]

 

rSBA ≥8% [95% CI]

9.6 [5.3–16.8]

92.3 [85.6–96.1]

78.8 [70.0–85.6]

98.1 [93.3–99.5]***

86.4 [78.5–91.7]#

 

rSBA ≥128% [95% CI]

6.7 [3.3–13.2]

90.4 [83.2–94.7]

72.1 [62.8–79.8]

96.2 [90.5–98.5]****

78.6 [69.8–85.5]##

 

IgG GMC [95%CI]; (µg/ml)

0.04 [0.03–0.05]

0.56 [0.37–0.85]

1.14 [0.84–1.54]

11.48 [9.04–14.59]

3.31 [2.56–4.29]

 

IgM GMC [95% CI]; (µg/ml)

0.03 [0.02–0.03]

0.58 [0.44–0.76]

0.18 [0.14–0.23]

0.36 [0.29–0.44]

0.23 [0.19–0.29]

MenY

rSBA GMT [95% CI]

2.7 [2.2–3.4]

643.5 [423.2–978.5]

93.0 [57.8–149.6]

400.1 [279.3–573.2]

126.7 [81.7–196.5]

 

rSBA ≥8% [95% CI]

4.8 [2.1–10.8]

91.3 [84.4–95.4]

76.9 [68.0–84.0]

94.2 [88.0–97.3]**

80.6 [71.9–87.1]#

 

rSBA ≥128% [95% CI]

3.8 [1.5–9.5]

87.5 [79.8–92.5]

62.5 [52.9–71.2]

84.6 [76.5–90.3]**

70.9 [61.5–78.8]

 

IgG GMC [95% CI]; (µg/ml)

0.04 [0.03–0.05]

2.04 [1.31–3.19]

1.72 [1.24–2.40]

18.09 [14.11–23.19]

4.07 [3.10–5.35]

 

IgM GMC [95% CI]; (µg/ml)

0.11 [0.09–0.13]

2.00 [1.46–2.72]

0.57 [0.44–0.73]

1.01 [0.81–1.27]

0.69 [0.55–0.85]

  1. Data shown are for the booster cohort (n = 104), which includes only participants who received a MenACWY-TT booster vaccination at one year (1 y) post primary vaccination. MenACWY-specific rSBA geometric mean titers (GMTs [95% CI]), IgG and IgM geometric mean concentrations (GMCs [95% CI], in µg/mL) were determined pre-booster (1 y), at one month (1 y + 1 m), and one year (1 y + 1 y) following booster vaccination. For reference, responses measured pre-primary vaccination and at one month (1 m) after primary vaccination are also shown for booster cohort participants. Proportions of participants with rSBA titers ≥8 and ≥128 [95% CI] were determined for each serogroup at each timepoint using the Wilson score interval with continuity correction, and compared using Fisher’s exact test, with Bonferroni correction applied for multiple testing. Comparisons were made for the following timepoints: * = 1 y vs. 1 y + 1 m; & = 1 y vs. 1 y + 1 y; # = 1 y + 1 m vs. 1 y + 1 y; @ = 1 m vs. 1 y + 1 m; P-value < 0.05*, <0.01**, <0.001***, <0.0001****.
Back to article page